Monoclonal Antibodies against Calcitonin Gene-Related Peptide for Migraine Prophylaxis: A Systematic Review of Real-World Data

被引:31
作者
Pavelic, Antun R. [1 ]
Woeber, Christian [2 ,3 ]
Riederer, Franz [1 ,4 ]
Zebenholzer, Karin [2 ,3 ]
机构
[1] Hietzing Hosp, Dept Neurol, A-1130 Vienna, Austria
[2] Med Univ Vienna, Dept Neurol, A-1090 Vienna, Austria
[3] Med Univ Vienna, Comprehens Ctr Clin Neurosci & Mental Hlth, A-1090 Vienna, Austria
[4] Univ Zurich, Fac Med, CH-8032 Zurich, Switzerland
关键词
real-world; erenumab; galcanezumab; fremanezumab; eptinezumab; pharmacoepidemiology; effectiveness; tolerability; safety; treatment pause; switching; PREVENTIVE TREATMENT; SUBGROUP ANALYSIS; DOUBLE-BLIND; MEDICATION OVERUSE; CGRP ANTIBODY; ERENUMAB; SAFETY; FREMANEZUMAB; GALCANEZUMAB; MULTICENTER;
D O I
10.3390/cells12010143
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Objective: To perform a systematic review of real-world outcomes for anti-CGRP-mAbs. Methods: Following the PRISMA guidelines, we searched PubMed for real-world data of erenumab, galcanezumab, fremanezumab, or eptinezumab in patients with migraines. Results: We identified 134 publications (89 retrospective), comprising 10 pharmaco-epidemiologic and 83 clinic-based studies, 38 case reports, and 3 other articles. None of the clinic-based studies provided follow-up data over more than one year in more than 200 patients. Findings suggest that there are reductions in health insurance claims and days with sick-leave as well as better treatment adherence with anti-CGRP-mAbs. Effectiveness, reported in 77 clinic-based studies, was comparable to randomized controlled trials. A treatment pause was associated with an increase in migraine frequency, and switching to another antibody resulted in a better response in some of the patients. Adverse events and safety issues were addressed in 86 papers, including 24 single case reports. Conclusion: Real-world data on anti-CGRP-mAbs are limited by retrospective data collection, small patient numbers, and short follow-up periods. The majority of papers seem to support good effectiveness and tolerability of anti-CGRP-mAbs in the real-world setting. There is an unmet need for large prospective real-world studies providing long-term follow-ups of patients treated with anti-CGRP-mAbs.
引用
收藏
页数:21
相关论文
共 175 条
[1]   Could erectile dysfunction be a side effect of CGRP inhibition? A case report [J].
Al-Hassany, Linda ;
Vries, Tessa de ;
Carpay, Johannes A. ;
MaassenVanDenBrink, Antoinette .
CEPHALALGIA, 2022, 42 (03) :257-261
[2]   Could the New Anti-CGRP Monoclonal Antibodies Be Effective in Migraine Aura? Case Reports and Literature Review [J].
Albanese, Maria ;
Mercuri, Nicola Biagio .
JOURNAL OF CLINICAL MEDICINE, 2022, 11 (05)
[3]   Safety and Tolerability of 3 CGRP Monoclonal Antibodies in Practice: A Retrospective Cohort Study [J].
Alex, Ashley ;
Vaughn, Caila ;
Rayhill, Melissa .
HEADACHE, 2020, 60 (10) :2454-2462
[4]   Real-world experience of erenumab in patients with chronic or episodic migraine in the UAE [J].
Alsaadi, Taoufik ;
Noori, Suzan ;
Varakian, Razmig ;
Youssef, Saly ;
Almadani, AbuBaker .
BMC NEUROLOGY, 2022, 22 (01)
[5]   Conversion from chronic to episodic migraine in patients treated with galcanezumab in real life in Italy: the 12-month observational, longitudinal, cohort multicenter GARLIT experience [J].
Altamura, Claudia ;
Brunelli, Nicoletta ;
Marcosano, Marilena ;
Aurilia, Cinzia ;
Egeo, Gabriella ;
Lovati, Carlo ;
Favoni, Valentina ;
Perrotta, Armando ;
Maestrini, Ilaria ;
Di Cola, Francesca Schiano ;
d'Onofrio, Florindo ;
Finocchi, Cinzia ;
Bertuzzo, Davide ;
Bono, Francesco ;
Ranieri, Angelo ;
Albanese, Maria ;
Messina, Roberta ;
Doretti, Alberto ;
Di Piero, Vittorio ;
Cevoli, Sabina ;
Barbanti, Piero ;
Vernieri, Fabrizio .
JOURNAL OF NEUROLOGY, 2022, 269 (11) :5848-5857
[6]   Two-year effectiveness of erenumab in resistant chronic migraine: a prospective real-world analysis [J].
Andreou, Anna P. ;
Fuccaro, Matteo ;
Hill, Bethany ;
Murphy, Madeleine ;
Caponnetto, Valeria ;
Kilner, Rachael ;
Lambru, Giorgio .
JOURNAL OF HEADACHE AND PAIN, 2022, 23 (01)
[7]   Ischemic Stroke Associated With Calcitonin Gene-Related Peptide Inhibitor Therapy for Migraine: A Case Report [J].
Aradi, Stephen ;
Kaiser, Eric ;
Cucchiara, Brett .
JOURNAL OF STROKE & CEREBROVASCULAR DISEASES, 2019, 28 (10)
[8]   Treatment-Refractory Headache in the Setting of COVID-19 Pneumonia: Migraine or Meningoencephalitis? Case Report [J].
Karissa N. Arca ;
Amaal J. Starling .
SN Comprehensive Clinical Medicine, 2020, 2 (8) :1200-1203
[9]   Erenumab and OnabotulinumtoxinA Combination Therapy for the Prevention of Intractable Chronic Migraine without Aura: A Retrospective Analysis [J].
Armanious, Mark ;
Khalil, Nadia ;
Lu, Yuanyuan ;
Jimenez-Sanders, Rebecca .
JOURNAL OF PAIN & PALLIATIVE CARE PHARMACOTHERAPY, 2021, 35 (01) :1-6
[10]   Long-term efficacy and safety of erenumab in migraine prevention: Results from a 5-year, open-label treatment phase of a randomized clinical trial [J].
Ashina, Messoud ;
Goadsby, Peter J. ;
Reuter, Uwe ;
Silberstein, Stephen ;
Dodick, David W. ;
Xue, Fei ;
Zhang, Feng ;
Paiva da Silva Lima, Gabriel ;
Cheng, Sunfa ;
Mikol, Daniel D. .
EUROPEAN JOURNAL OF NEUROLOGY, 2021, 28 (05) :1716-1725